Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

AIVITA Biomedical

  • Hans Keirstead, AIVITA Biomedical, Inc.

AIVITA Biomedical is a clinical stage biotech developing next generation immunotherapies. We leverage our expertise with stem cells to develop therapies to treat solid tumor cancers. Our platform technology isolates and propagates tumor-initiating cells (or cancer stem cells), responsible for metastases of cancers, to target the full patient-specific antigenic profile of that patient's tumor. When presented by the patient's dendritic cells, these antigens are recognized by the immune system and targeted for termination. Exposing the full antigenic load of the tumor means the immune system may be able to identify mutated or dormant tumor-initiating cells, improving the patient's ability to fight the disease.

In addition to two phase 2 studies in the US, we have a pivotal trial in Japan in metastatic melanoma starting Q1 2019.

Our platform technology is autologous cell therapy. We have robust data in efficacy and mechanism of action and a low-cost, efficient manufacturing proc

  • Date:Tuesday, February 12
  • Time:1:45 PM - 2:00 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23318
  • Goal for Presentation:Raise profile of company and seek new investors
  • Company Website:www.aivitabiomedical.com
  • Company HQ City:Irvine
  • Company HQ State:California
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$22.25 million
  • Size of Last Investment Round:$16.25 million
  • CEO/Top Company Official:Hans Keirstead
  • Year Founded:2016
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Dendritic cell vaccine in ovarian cancer and glioblastoma
  • Development Phase of Primary Product:Phase II
Speakers
Hans Keirstead
AIVITA Biomedical, Inc.
Back